JP2562827B2 - アジュバント混合物 - Google Patents

アジュバント混合物

Info

Publication number
JP2562827B2
JP2562827B2 JP63063073A JP6307388A JP2562827B2 JP 2562827 B2 JP2562827 B2 JP 2562827B2 JP 63063073 A JP63063073 A JP 63063073A JP 6307388 A JP6307388 A JP 6307388A JP 2562827 B2 JP2562827 B2 JP 2562827B2
Authority
JP
Japan
Prior art keywords
pathogen
adjuvant
adjuvant mixture
oil
polyoxypropylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP63063073A
Other languages
English (en)
Japanese (ja)
Other versions
JPS63253032A (ja
Inventor
エリツク・オンノ・リイケ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo NV
Original Assignee
Akzo NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo NV filed Critical Akzo NV
Publication of JPS63253032A publication Critical patent/JPS63253032A/ja
Application granted granted Critical
Publication of JP2562827B2 publication Critical patent/JP2562827B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP63063073A 1987-03-17 1988-03-16 アジュバント混合物 Expired - Fee Related JP2562827B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL8700629 1987-03-17
NL8700629 1987-03-17

Publications (2)

Publication Number Publication Date
JPS63253032A JPS63253032A (ja) 1988-10-20
JP2562827B2 true JP2562827B2 (ja) 1996-12-11

Family

ID=19849718

Family Applications (1)

Application Number Title Priority Date Filing Date
JP63063073A Expired - Fee Related JP2562827B2 (ja) 1987-03-17 1988-03-16 アジュバント混合物

Country Status (9)

Country Link
US (1) US5026543A (enExample)
EP (1) EP0283085B1 (enExample)
JP (1) JP2562827B2 (enExample)
DE (1) DE3875762T2 (enExample)
DK (1) DK167849B1 (enExample)
ES (1) ES2052685T3 (enExample)
GR (1) GR3007039T3 (enExample)
HU (1) HU202119B (enExample)
ZA (1) ZA881694B (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
CN1120310A (zh) * 1993-03-11 1996-04-10 塞科雷泰克公司 在粘膜表面转运免疫原的聚合粘膜粘合剂
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
WO1995011700A1 (en) * 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9417742D0 (en) * 1994-09-03 1994-10-19 Univ Nottingham Macrophage stimulating composition
BE1008977A5 (fr) * 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
US5891393A (en) * 1996-04-09 1999-04-06 The University Of North Carolina At Chapel Hill Method for the microbial decontamination of blood platelets
GB9622159D0 (en) * 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
US6197327B1 (en) * 1997-06-11 2001-03-06 Umd, Inc. Device and method for treatment of dysmenorrhea
US6416779B1 (en) 1997-06-11 2002-07-09 Umd, Inc. Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
US6572874B1 (en) 1998-05-15 2003-06-03 Umd, Inc. Vaginal delivery of bisphosphonates
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
FR2776928B1 (fr) 1998-04-03 2000-06-23 Merial Sas Vaccins adn adjuves
NZ514323A (en) * 1999-03-24 2003-03-28 Secr Defence A immunostimulant containing an acitive agent and an adjuvant which increases the effect of the active agent
US6943152B1 (en) * 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
US7018638B2 (en) 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
MY129765A (en) 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
US6676958B2 (en) * 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
EP1594524B1 (en) 2003-01-21 2012-08-15 Novartis Vaccines and Diagnostics, Inc. Use of tryptanthrin compounds for immune potentiation
EP2258365B1 (en) 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
EP1765313A2 (en) 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
WO2007079147A2 (en) 2005-12-28 2007-07-12 Advanced Bionutrition Corporation A delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
US20080226669A1 (en) 2005-12-29 2008-09-18 Boehringer Ingelheim Vetmedica, Inc. Multivalent pcv2 immunogenic compositions and methods of producing such compositions
DK3127551T3 (da) 2005-12-29 2020-10-12 Boehringer Ingelheim Animal Health Usa Inc Pcv2-immunogen-sammensætning til at mindske kliniske symptomer i grise
EP2010537B1 (en) 2006-03-23 2011-12-28 Novartis AG Imidazoquinoxaline compounds as immunomodulators
ES2388556T3 (es) * 2006-03-23 2012-10-16 Novartis Ag Compuestos inmunopotenciadores
EP2010530A2 (en) * 2006-03-23 2009-01-07 Novartis AG Methods for the preparation of imidazole-containing compounds
US20100129397A1 (en) 2006-12-11 2010-05-27 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US20080292663A1 (en) * 2007-05-22 2008-11-27 Gerber Jay D Adjuvant compositions and methods for delivering vaccines
JP5613061B2 (ja) 2008-01-23 2014-10-22 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド Ｐｃｖ２マイコプラズマ・ハイオニューモニエ免疫原性組成物および前記組成物の製造方法
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
JP5762307B2 (ja) * 2009-03-31 2015-08-12 国立感染症研究所長 経鼻投与用ワクチンを用いるインフルエンザの予防方法
JP5841527B2 (ja) 2009-05-26 2016-01-13 アドバンスド バイオニュートリション コーポレーション 生物学的に活性な微生物および／または生物活性材料を含む安定な乾燥粉末組成物およびその製造方法
AR080073A1 (es) 2010-01-28 2012-03-14 Advanced Bionutrition Corp Composicion vitrea seca que comprende un material bioactivo
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
EP4218808A3 (en) 2012-03-12 2023-08-09 Advanced BioAdjuvants, LLC Adjuvant and vaccine compositions
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
JP6778104B2 (ja) 2013-10-02 2020-10-28 ベーリンガー・インゲルハイム・アニマル・ヘルス・ユーエスエー・インコーポレイテッドＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ａｎｉｍａｌ Ｈｅａｌｔｈ Ｕｓａ Ｉｎｃ． Ｐｃｖ２ ｏｒｆ２タンパク質変種および前記を含むウイルス様粒子
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
US10953050B2 (en) 2015-07-29 2021-03-23 Advanced Bionutrition Corp. Stable dry probiotic compositions for special dietary uses
TW202015725A (zh) 2018-06-04 2020-05-01 美商亞博創新醫藥有限公司 Tlr7 肽結合物
AU2019297321B2 (en) 2018-07-02 2022-02-03 Ayuvis Research, Inc. Novel immunodulating small molecules

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3178350A (en) * 1961-05-15 1965-04-13 Cutler Lab Inc Biologic antigens adjuvanted with a colloidally water-soluble polymer of acrylic acidcrosslinked with polyallyl sucrose or polyallyl pentaerythritol
US3919411A (en) * 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
US3869546A (en) * 1972-12-22 1975-03-04 Cutter Lab Adjuvant compositions and medicinal mixtures comprising them
DE3308458A1 (de) * 1983-03-10 1984-09-13 Behringwerke Ag, 3550 Marburg Verfahren zur adjuvierung von vaccinen
US4567043A (en) * 1983-06-15 1986-01-28 American Home Products Corporation (Del.) Canine corona virus vaccine
US4567042A (en) * 1983-06-15 1986-01-28 American Home Products Corporation Inactivated canine coronavirus vaccine
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants

Also Published As

Publication number Publication date
DE3875762T2 (de) 1993-05-13
GR3007039T3 (enExample) 1993-07-30
JPS63253032A (ja) 1988-10-20
DE3875762D1 (de) 1992-12-17
DK167849B1 (da) 1993-12-27
US5026543A (en) 1991-06-25
HUT47224A (en) 1989-02-28
HU202119B (en) 1991-02-28
EP0283085A1 (en) 1988-09-21
ZA881694B (en) 1988-09-06
ES2052685T3 (es) 1994-07-16
DK141488D0 (da) 1988-03-15
EP0283085B1 (en) 1992-11-11
DK141488A (da) 1988-09-18

Similar Documents

Publication Publication Date Title
JP2562827B2 (ja) アジュバント混合物
JP5074656B2 (ja) 改良されたマイコプラズマハイオニューモニエバクテリンワクチン
US5565209A (en) Adjuvant mixture
US20080003201A1 (en) Interleukin-12 as a veterinary vaccine adjuvant
HU206989B (en) Process for producing vaccines comprising tocols as adjuvant
KR20050103215A (ko) 보르데텔라 브론키셉티카에 대한 개 백신
JP2004536106A (ja) マイコプラズマ・ボビスワクチンおよび動物の肺炎を減少させる方法
US20050202046A1 (en) Canine vaccine for protection against ehrlichiosis
Miao et al. Enhanced immune response to rabies viruses by the use of a liposome adjuvant in vaccines
US6936260B1 (en) Vaccine composition
CN111888468B (zh) 一种免疫水佐剂及其制备方法
JP5470052B2 (ja) 動物の感染症を治療または予防するための免疫原組成物
CN110507819B (zh) 青蒿琥酯作为免疫佐剂在制备狂犬病疫苗中的应用
Rehmani et al. The influence of adjuvants on oral vaccination of chickens against Newcastle disease
JP2012504118A (ja) ワクチンアジュバント
Babudieri et al. Comparative tests with formolized and irradiated vaccines against leptospirosis
Chen et al. Comparison of the immune response to three different Yersinia pestis vaccines in guinea pigs and langurs
US20090087456A1 (en) Adjuvanted vaccine
Mutwiri et al. ALEXANDER K. ANDRIANOV
Okerman et al. Failure of oil adjuvants to enhance immunity induced in mice by an inactivated rabbit Pasteurella multocida vaccine
WO2023240278A2 (en) Uses of glycolipids as a vaccine adjuvant and methods thereof
EP0085469A1 (en) Method of preparing an immunogen of Pasteurella multocida
Basu et al. Studies on immunomodulatory effect of levamisole and stressroak in chicks vaccinated with different Newcastle disease (ND) vaccines
Montbrau et al. EFFICACY OF ERAVAC® AGAINST A HETEROLOGOUS CHALLENGE WITH A VIRULENT RHDV-2 STRAIN IN THE PRESENCE AND/OR ABSENCE OF MATERNAL DERIVED ANTIBODIES
AU2002335754A1 (en) Interleukin-12 as a veterinary vaccine adjuvant

Legal Events

Date Code Title Description
LAPS Cancellation because of no payment of annual fees